Advertisement

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Sponsored by Pfizer

Phase Quota
Phase 1

This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.

Study Start Date: July 2011

Estimated Completion Date: August 2014

Specialties: Neurology: Dementia,Neuro/Psych pharmacology Pharmacy: Drug Trials,Neuro/Psych pharmacology

Interventions

  • Drug: AAB-003 (PF-05236812)

Inclusion criteria

  • Successful completion of study B2601001
  • MMSE 12 or greater

Exclusion criteria

  • Study B2601001 Week 32 MRI with clinically important exclusionary findings.
  • Experienced SAE, vasogenic edema and/or intracranial hemorrhage in study B2601001

Study Locations And Contact Information

  • Pfizer Investigational Site, Rockville Maryland
  • Pfizer Investigational Site, Seoul
  • Pfizer Investigational Site, Hallandale Beach Florida
  • Pfizer Investigational Site, Seoul
  • Pfizer Investigational Site, Eatontown New Jersey
  • Pfizer Investigational Site, Kalamazoo Michigan
  • Pfizer Investigational Site, Seoul
  • Pfizer Investigational Site, Seongnam-si Gyeonggi-do
  • Pfizer Investigational Site, Oakhurst New Jersey
  • Pfizer Investigational Site, Seoul
  • Pfizer Investigational Site, Incheon
  • Pfizer Investigational Site, Ocala Florida
  • Pfizer Investigational Site, Creve Coeur Missouri
  • Pfizer Investigational Site, Ocala Florida
  • Pfizer Investigational Site, St. Louis Missouri
  • Pfizer Investigational Site, Bethesda Maryland
  • Pfizer Investigational Site, Atlanta Georgia

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit ClinicalTrialsLocator.com to find out how you can feature this clinical trial.

Advertisement